COVID-19: How and when to take DRDO's 2DG drug - Check guidelines here freepressjournal.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from freepressjournal.in Daily Mail and Mail on Sunday newspapers.
DNA Explainer: How to administer 2-DG drug on COVID-19 patients, DRDO guidelines - The oral drug cleared by the Drugs Controller General of India on May 1 for emergency use, is an adjunct therapy to treat severe COVID-19 patients.
New Delhi [India], June 1 (ANI): The Defence Research and Development Organisation's (DRDO) on Tuesday said that the anti-COVID drug 2DG is approved for emergency use as an adjunct therapy to the standard of care in the treatment of coronavirus patients in hospital settings.
DRDO issues directions on usage of anti-COVID drug 2-DG
SECTIONS
Last Updated: Jun 01, 2021, 08:40 PM IST
Share
Synopsis
The Drugs Controller General of India (DCGI) approved the 2-deoxy-D-glucose (2-DG) drug for emergency use as an adjunct therapy in moderate to severe coronavirus patients in early May. The first batch of this oral drug, developed by the Defence Research and Development Organisation (DRDO), was released on May 17 by Defence Minister Rajnath Singh and Health Minister Harsh Vardhan.
Agencies
The DRDO said the drug is approved for emergency use as adjunct therapy to the standard treatment of COVID-19 patients in the hospital settings.
The Defence Research and Development Organisation`s (DRDO) on Tuesday (June 1) said that the anti-COVID drug 2DG is approved for emergency use as an adjunct therapy to the standard of care in the treatment of coronavirus patients in hospital settings.
Read more about DRDO issues directions on usage of anti-coronavirus drug 2-DG on patients on Business Standard. The DRDO issued directions on the usage of its 2-DG drug on COVID-19 patients, stating that caution should be exercised while prescribing this medicine to people who have comorbidites
URL copied
2-DG: How and when to use DRDO's anti-Covid drug? Guidelines
Defence Research and Development Organisation (DRDO) on Tuesday released guidelines on how and when to use its anti-Covid medicine 2-Deoxy-d-glucose (2-DG) medicine. The drug was launched last month by the Ministry of Defence. It has been developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a leading laboratory of the DRDO, in collaboration with Dr Reddy's Laboratories (DRL) in Hyderabad.
The DRDO said that 2-DG medicine should be used under the supervision of a doctor. The oral drug for emergency use is an adjunct therapy to treat severe Covid patients. It reduces dependence on supplemental oxygen.
India News: The DRDO on Tuesday issued directions on the usage of its 2-DG drug on Covid-19 patients, stating that caution should be exercised while prescribing t
Pic credit: ANI
NEW DELHI: The Defence Research and Development Organisation's (DRDO) on Tuesday said that the anti-Covid drug 2DG is
approved for emergency use as an adjunct therapy to the standard of care in the treatment of coronavirus patients in hospital settings. The DRDO said that anti-Covid drug 2DG can now be given to Covid 19 patients under the care and prescription of doctors. DRDO also issued some important guidelines with regard to its anti-Covid -19 drug. "Ideally, 2DG should be prescribed as early as possible by doctors for moderate to severe Covid patients for a maximum duration of up to 10 days," it said.
Dr Reddy's Labarotaries has announced the price of 2-DG drug for Covid-19 patients at Rs 990 per sachet, developed by DRDO in collaboration with Dr Reddys. Government hospitals, central and state governments would be provided with the medicine at a discounted price, said an official. This drug is available in powder form and can be consumed orally by dissolving it in water.